Carol M. Lewis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carol M. Lewis has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Randal S. Weber
Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
15 shared publicationsZhannat Nurgalieva
Department of Head and Neck Surgery, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
6 shared publications- Kimberley Liqin Kiong
Department of Otorhinolaryngology—Head & Neck Surgery Singapore General Hospital Singapore Singapore
5 shared publications - Samantha Tam
Department of Otolaryngology-Head and Neck Surgery, Henry Ford Health, Detroit, MI
5 shared publications - Stephen Y. Lai
Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA
4 shared publications - Erich M. Sturgis
Department of Otolaryngology-Head and Neck Surgery, Baylor College Of Medicine, Houston, Texas
3 shared publications
Latest Publications
- 17 May 2022
- Published by Elsevier in Oral Oncology
- Vol. 130, 105906
Enhanced recovery after surgery (ERAS) in head and neck oncologic surgery: Impact on return to intended oncologic therapy (RIOT) and survival
- 17 May 2022
- Published by Elsevier in Oral Oncology
- Vol. 130, 105906
Enhanced recovery after surgery (ERAS) in head and neck oncologic surgery: Impact on return to intended oncologic therapy (RIOT) and survival
- 1 November 2021
- Published by Elsevier in Oral Oncology
- Vol. 122, 105520
Multifocal regression and pathologic response predicts recurrence after neoadjuvant chemotherapy in head and neck squamous cell carcinoma
- 1 November 2021
- Published by Elsevier in Oral Oncology
- Vol. 122, 105520
Multifocal regression and pathologic response predicts recurrence after neoadjuvant chemotherapy in head and neck squamous cell carcinoma
Delay to surgery after neoadjuvant chemotherapy in head and neck squamous cell carcinoma affects oncologic outcomes
Background: Neoadjuvant chemotherapy (NAC) is used in head and neck squamous cell carcinoma (HNSCC) for downstaging advanced disease and decreasing distant metastasis (DM). To the authors' knowledge, no study has specifically examined the impact of a delayed time to surgery (TTS) after NAC on oncologic outcomes. They thus aimed to identify a cutoff for TTS after NAC and its effect on survival indices.Methods: This was a retrospective review of all patients with HNSCC receiving NAC followed by surgery with curative intent between March 2016 and March 2019 at the MD Anderson Cancer Center. Receiver operating characteristic analysis was used to identify a cutoff for TTS, and this cutoff was used to analyze the overall survival (OS), locoregional recurrence rate, DM‐free rate, and disease‐free survival (DFS). A multivariate Cox regression analysis was performed.Results: One hundred one patients were analyzed with a median follow‐up of 24.7 months. The 3‐year OS and locoregional recurrence rates did not differ with a TTS ≥ 34 days. However, the 3‐year DM‐free rate was significantly worse (56% vs 90%; P = .001) in the group with a TTS ≥ 34 days, and the 3‐year DFS was significantly lower (26% vs 64%; P = .006). In a multivariate analysis, a TTS ≥ 34 days (hazard ratio [HR], 4.92; 95% confidence interval [CI], 1.84‐13.13) and extracapsular extension (HR, 3.01; 95% CI, 1.13‐8.00) were significant independent predictors of a poorer DM‐free rate. Weight loss > 10% (HR, 5.53; 95% CI, 1.02‐30.24) was the only independent predictor for a TTS ≥ 34 days.Conclusions: Emphasis should be placed on early definitive locoregional treatment after NAC, particularly in patients who do not respond to NAC. There is a need to validate these findings and establish new benchmarks for the interval between NAC and surgery.
Delay to surgery after neoadjuvant chemotherapy in head and neck squamous cell carcinoma affects oncologic outcomes
Background: Neoadjuvant chemotherapy (NAC) is used in head and neck squamous cell carcinoma (HNSCC) for downstaging advanced disease and decreasing distant metastasis (DM). To the authors' knowledge, no study has specifically examined the impact of a delayed time to surgery (TTS) after NAC on oncologic outcomes. They thus aimed to identify a cutoff for TTS after NAC and its effect on survival indices.Methods: This was a retrospective review of all patients with HNSCC receiving NAC followed by surgery with curative intent between March 2016 and March 2019 at the MD Anderson Cancer Center. Receiver operating characteristic analysis was used to identify a cutoff for TTS, and this cutoff was used to analyze the overall survival (OS), locoregional recurrence rate, DM‐free rate, and disease‐free survival (DFS). A multivariate Cox regression analysis was performed.Results: One hundred one patients were analyzed with a median follow‐up of 24.7 months. The 3‐year OS and locoregional recurrence rates did not differ with a TTS ≥ 34 days. However, the 3‐year DM‐free rate was significantly worse (56% vs 90%; P = .001) in the group with a TTS ≥ 34 days, and the 3‐year DFS was significantly lower (26% vs 64%; P = .006). In a multivariate analysis, a TTS ≥ 34 days (hazard ratio [HR], 4.92; 95% confidence interval [CI], 1.84‐13.13) and extracapsular extension (HR, 3.01; 95% CI, 1.13‐8.00) were significant independent predictors of a poorer DM‐free rate. Weight loss > 10% (HR, 5.53; 95% CI, 1.02‐30.24) was the only independent predictor for a TTS ≥ 34 days.Conclusions: Emphasis should be placed on early definitive locoregional treatment after NAC, particularly in patients who do not respond to NAC. There is a need to validate these findings and establish new benchmarks for the interval between NAC and surgery.
Impact of provider type and number of providers on surveillance testing among survivors of head and neck cancers
Background: Guidelines for follow‐up after head and neck cancer (HNC) treatment recommend frequent clinical examinations and surveillance testing. Here, the authors describe real‐world follow‐up care for HNC survivors and variations in surveillance testing.Methods: Using Surveillance, Epidemiology, and End Results (SEER)–Medicare data, this study examined a population‐based cohort of HNC survivors between 2001 and 2011 Usage of cross‐sectional head and neck imaging (CHNI), chest imaging (CI), positron emission tomography (PET), fiberoptic nasopharyngolaryngoscopy (FNPL), and, in irradiated patients, thyroid function testing (TFT) was captured over 2 consecutive surveillance years. Multivariate modeling with logistic regression analyses was used to assess variations by clinical factors, nonclinical factors, number and types of providers seen and their evolution over time.Results: Among 13,836 HNC survivors, the majority saw a medical, radiation, or surgical oncologist and a primary care provider (PCP; 81.7%) in their first year of surveillance. However, only 58.1% underwent either PET or CHNI, 47.8% underwent CHNI, 64.1% underwent CI, 32.5% underwent PET scans, 55.0% underwent FNPL, and 55.9% underwent TFT. In multivariate analyses, patients who followed up with more providers and those who followed up with both a PCP and an oncologist were more likely to undergo surveillance testing (P < .007). However, adjusting for providers seen did not explain the variations in surveillance testing rates based on age, race, education, income level, and place of residence. Over time, there was a gradual increase in the use of PET scans and TFT during surveillance years.Conclusions: In this large SEER‐Medicare data study, only half of HNC survivors received the recommended testing, and greater compliance was seen in those who followed up with both an oncologist and a PCP. More attention is needed to minimize variations in surveillance testing across sociodemographic groups.
Impact of provider type and number of providers on surveillance testing among survivors of head and neck cancers
Background: Guidelines for follow‐up after head and neck cancer (HNC) treatment recommend frequent clinical examinations and surveillance testing. Here, the authors describe real‐world follow‐up care for HNC survivors and variations in surveillance testing.Methods: Using Surveillance, Epidemiology, and End Results (SEER)–Medicare data, this study examined a population‐based cohort of HNC survivors between 2001 and 2011 Usage of cross‐sectional head and neck imaging (CHNI), chest imaging (CI), positron emission tomography (PET), fiberoptic nasopharyngolaryngoscopy (FNPL), and, in irradiated patients, thyroid function testing (TFT) was captured over 2 consecutive surveillance years. Multivariate modeling with logistic regression analyses was used to assess variations by clinical factors, nonclinical factors, number and types of providers seen and their evolution over time.Results: Among 13,836 HNC survivors, the majority saw a medical, radiation, or surgical oncologist and a primary care provider (PCP; 81.7%) in their first year of surveillance. However, only 58.1% underwent either PET or CHNI, 47.8% underwent CHNI, 64.1% underwent CI, 32.5% underwent PET scans, 55.0% underwent FNPL, and 55.9% underwent TFT. In multivariate analyses, patients who followed up with more providers and those who followed up with both a PCP and an oncologist were more likely to undergo surveillance testing (P < .007). However, adjusting for providers seen did not explain the variations in surveillance testing rates based on age, race, education, income level, and place of residence. Over time, there was a gradual increase in the use of PET scans and TFT during surveillance years.Conclusions: In this large SEER‐Medicare data study, only half of HNC survivors received the recommended testing, and greater compliance was seen in those who followed up with both an oncologist and a PCP. More attention is needed to minimize variations in surveillance testing across sociodemographic groups.
- 1 December 2020
- Published by Elsevier in Oral Oncology
- Vol. 111, 104917
Risk-adjustment models in patients undergoing head and neck surgery with reconstruction
- 1 December 2020
- Published by Elsevier in Oral Oncology
- Vol. 111, 104917
Risk-adjustment models in patients undergoing head and neck surgery with reconstruction
- 1 November 2020
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 41 (6) , 102679
Feasibility of an Enhanced Recovery After Surgery (ERAS) pathway for major head and neck oncologic surgery
- 1 November 2020
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 41 (6) , 102679
Feasibility of an Enhanced Recovery After Surgery (ERAS) pathway for major head and neck oncologic surgery
- 22 September 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (2) , 867-876
Enhanced Recovery After Surgery (ERAS) in Head and Neck Oncologic Surgery: A Case-Matched Analysis of Perioperative and Pain Outcomes
Enhanced recovery after surgery (ERAS) pathways are well established in certain surgical specialties because findings have shown significant improvements i
- 22 September 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (2) , 867-876
Enhanced Recovery After Surgery (ERAS) in Head and Neck Oncologic Surgery: A Case-Matched Analysis of Perioperative and Pain Outcomes
Enhanced recovery after surgery (ERAS) pathways are well established in certain surgical specialties because findings have shown significant improvements i
Impact of neoadjuvant chemotherapy on perioperative morbidity after major surgery for head and neck cancer
Background: Neoadjuvant chemotherapy (NAC) has been used in patients with advanced head and neck cancers (HNCs) with the intent of downstaging tumors and suppressing distant metastases. However, to the authors' knowledge, the perioperative impact of NAC has not been systematically explored in patients with HNC. The objective of the current study was to compare perioperative outcomes with surgery upfront compared with patients treated with NAC.Methods: Between March 1, 2016, and March 31, 2019, patients undergoing surgery for HNC with flap reconstruction at The University of Texas MD Anderson Cancer Center in Houston were included. Data were extracted from the prospectively maintained National Surgical Quality Improvement Program database. Postoperative complications, return to operating room, and readmission rates were compared. Univariate and multivariate analyses of length of stay and overall and wound complications were performed.Results: A total of 834 patients were analyzed, 687 of whom (82.4%) underwent surgery upfront and 147 of whom (17.6%) received NAC. A total of 631 cases (75.7%) involved the upper aerodigestive tract whereas 203 cases (24.3%) were cutaneous. A total of 317 patients (38.0%) had recurrent disease. The NAC group was younger (P < .001) and had less hypertension (P = .011), but had more advanced clinical stage tumors (P < .001) and surgeries with multiple flap reconstruction (P = .007). Patient groups did not differ with regard to wound complications (P = .47), return to operating room (P = .31), or readmission rates (P = .49). The NAC group received more blood transfusions (P < .001) but was found to have a lower risk of overall complications on multivariate analysis (odds ratio, 0.50; 95% CI, 0.30‐0.83). The overall complication rate was unchanged with surgery performed ≤21 days after the last chemotherapy cycle.Conclusions: Patients undergoing NAC appear to have a higher disease burden but tend to be younger and healthier. Within the context of this inherent selection bias, NAC does not appear to increase perioperative morbidity among patients undergoing surgery for HNC.
Impact of neoadjuvant chemotherapy on perioperative morbidity after major surgery for head and neck cancer
Background: Neoadjuvant chemotherapy (NAC) has been used in patients with advanced head and neck cancers (HNCs) with the intent of downstaging tumors and suppressing distant metastases. However, to the authors' knowledge, the perioperative impact of NAC has not been systematically explored in patients with HNC. The objective of the current study was to compare perioperative outcomes with surgery upfront compared with patients treated with NAC.Methods: Between March 1, 2016, and March 31, 2019, patients undergoing surgery for HNC with flap reconstruction at The University of Texas MD Anderson Cancer Center in Houston were included. Data were extracted from the prospectively maintained National Surgical Quality Improvement Program database. Postoperative complications, return to operating room, and readmission rates were compared. Univariate and multivariate analyses of length of stay and overall and wound complications were performed.Results: A total of 834 patients were analyzed, 687 of whom (82.4%) underwent surgery upfront and 147 of whom (17.6%) received NAC. A total of 631 cases (75.7%) involved the upper aerodigestive tract whereas 203 cases (24.3%) were cutaneous. A total of 317 patients (38.0%) had recurrent disease. The NAC group was younger (P < .001) and had less hypertension (P = .011), but had more advanced clinical stage tumors (P < .001) and surgeries with multiple flap reconstruction (P = .007). Patient groups did not differ with regard to wound complications (P = .47), return to operating room (P = .31), or readmission rates (P = .49). The NAC group received more blood transfusions (P < .001) but was found to have a lower risk of overall complications on multivariate analysis (odds ratio, 0.50; 95% CI, 0.30‐0.83). The overall complication rate was unchanged with surgery performed ≤21 days after the last chemotherapy cycle.Conclusions: Patients undergoing NAC appear to have a higher disease burden but tend to be younger and healthier. Within the context of this inherent selection bias, NAC does not appear to increase perioperative morbidity among patients undergoing surgery for HNC.
- 9 September 2019
- Published by Wiley in Head & Neck
- Vol. 41 (11) , 3960-3969
Adherence with National Comprehensive Cancer Network posttreatment surveillance guidelines in patients with head and neck cancer
Background: Surveillance in head and neck cancer (HNC) is essential to detect recurrent or new lesions and to optimize function. This study describes drivers of surveillance adherence in patients with HNC and its effect on prognosis.Methods: Adherence with surveillance of HNC patients was determined using the National Comprehensive Cancer Network HNC guidelines. Logistic regression and Cox proportional hazards models were used to determine predictors of adherence and overall survival (OS).Results: Results showed that 110 of 221 patients (50.2%) were adherent with surveillance. Distance from the treatment center was the only significant association. Adherence was not associated with OS following multivariate adjustment (adjusted hazard ratio [aHR] = 0.68, 95% confidence interval [CI] = 0.43‐1.09). However, 5‐10 years after treatment completion, adherence was an independent predictor of survival (aHR = 0.24, 95% CI = 0.09‐0.61).Conclusion: Adherence with surveillance is important in improving survival in patients with HNC, especially in the long term.
- 9 September 2019
- Published by Wiley in Head & Neck
- Vol. 41 (11) , 3960-3969
Adherence with National Comprehensive Cancer Network posttreatment surveillance guidelines in patients with head and neck cancer
Background: Surveillance in head and neck cancer (HNC) is essential to detect recurrent or new lesions and to optimize function. This study describes drivers of surveillance adherence in patients with HNC and its effect on prognosis.Methods: Adherence with surveillance of HNC patients was determined using the National Comprehensive Cancer Network HNC guidelines. Logistic regression and Cox proportional hazards models were used to determine predictors of adherence and overall survival (OS).Results: Results showed that 110 of 221 patients (50.2%) were adherent with surveillance. Distance from the treatment center was the only significant association. Adherence was not associated with OS following multivariate adjustment (adjusted hazard ratio [aHR] = 0.68, 95% confidence interval [CI] = 0.43‐1.09). However, 5‐10 years after treatment completion, adherence was an independent predictor of survival (aHR = 0.24, 95% CI = 0.09‐0.61).Conclusion: Adherence with surveillance is important in improving survival in patients with HNC, especially in the long term.